Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment.

Slides:

Advertisements

Similar presentations

3.What is the principle behind the Quantiferon-Tb assay for TB?

Advertisements

The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and.

Indeterminate and inconclusive results are common when using Interferon Gamma Release Assay as screening for TB in patients with IBD Nasr I, Goel RM, Ward.

Serta Kılınçalp, Akif Altınbaş, Ömer Başar, Murat Deveci, Osman Yüksel

Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review X.-F. Gao, Z.-W. Yang, J. Li International.

Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease Giammarco Mocci, Manuela Marzo, Alfredo Papa, Alessandro.

Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease—what is the role of anti-TNF antibody?

Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events Fernando Magro, Manuel.

Volume 73, Issue 6, Pages (December 2016)

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

YouTube® and inflammatory bowel disease

Liver abscess of the caudate lobe due to Staphylococcus aureus in an ulcerative colitis patient: First case report Andreia Albuquerque, Fernando Magro,

Primary biliary cirrhosis developing in a patient with Crohn's disease during the course of infliximab treatment: The first case in the literature Gurhan.

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis Vincent Billioud, Alexander C. Ford,

Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD) Mariam Aguas, Vicente Garrigues,

From: Treatment of Refractory Whipple Disease with Interferon-γ

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

Volume 66, Issue 6, Pages (June 2013)

Anterior ischemic optic neuropathy in a patient with Crohn's disease and aberrant MTHFR and GPIIIa gene variants T. Felekis, K.H. Katsanos, C.D. Zois,

Serum prohepcidin levels in chronic inflammatory bowel diseases

Hemophagocytic syndrome in a child with severe Crohn's disease and familial Mediterranean fever Nuray Uslu, Hulya Demir, Gunay Balta, Inci N Saltik-Temizel,

Charlotte de Bie, Angelika Kindermann, Johanna Escher

N. Kjaersgaard Nielsen, V. Wewer, L. Skafte, A. Paerregaard

Hemophagocytic syndrome in a child with severe Crohn's disease and familial Mediterranean fever Nuray Uslu, Hulya Demir, Gunay Balta, Inci N Saltik-Temizel,

Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events Fernando Magro, Manuel.

Public awareness of Crohn's disease and ulcerative colitis: A national survey Sieglinde Angelberger, Harald Vogelsang, Gottfried Novacek, Wolfgang Miehsler,

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

B. Sicilia, F. Arribas, J. Nerín, C. López Miguel, R. Vicente, F

Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases Danuta Owczarek,

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease Gord Blackhouse, Nazila Assasi,

Current Concepts in the Management of Tuberculosis

Volume 19, Issue 12, Pages (December 2011)

Feasibility of commercial interferon-γ-based methods for the diagnosis of latent Mycobacterium tuberculosis infection in Finland, a country of low incidence.

Volume 140, Issue 2, Pages e1 (February 2011)

Benefit of ELISpot in early diagnosis of tuberculous meningoencephalitis: Case report and literature review Josefine Blume, Josef Köstler, Robert Weissert

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Diagnostic Performance of a Cytokine and IFN-γ–Induced Chemokine mRNA Assay after Mycobacterium tuberculosis–Specific Antigen Stimulation in Whole Blood.

Current Concepts in the Management of Tuberculosis

Paula Borralho, Ana Vieira, João Freitas, Paula Chaves, Jorge Soares

Clinical trials in luminal Crohn's disease: A historical perspective

Xian-rui Wu, Saurabh Mukewar, Ravi P. Kiran, Feza H

Rapid improvement of refractory pyoderma gangrenosum with infliximab gel in a patient with ulcerative colitis Niels Teich, Tobias Klugmann Journal of.

Seth Lipka, Seymour Katz, Lev Ginzburg Journal of Crohn's and Colitis

Osteoporosis in inflammatory bowel disease

Time for a change? Updated guidelines using interferon gamma release assays for detection of latent tuberculosis infection in the office setting Marisa.

Tuberculosis Terpene Targets

Volume 54, Issue 4, Pages (October 1998)

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis M. De Vos, O. Dewit, G. D'Haens,

Pilot Study of 1650-G: A Simplified Cellular Vaccine for Lung Cancer

“Ulcerative crepitus” — A case with subcutaneous emphysema and pneumomediastinum without colonic perforation or toxic megacolon in ulcerative colitis.

Ulrich Bonse-Geuking, Michael Kraus Journal of Crohn's and Colitis

Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease Gord Blackhouse, Nazila Assasi,

Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA- based protocol in UK subjects with inflammatory bowel disease suitable.

Does active smoking really influence the course of Crohn's disease

Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function Ulf Hindorf, Malin Lindqvist.

Yinghong Wang, Hua Gong, Rocio Lopez, Lei Lian, Ravi P. Kiran, Edy E

Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and infliximab Antonio López San Román, Manuel.

Exclusive elemental diet impacts on the gastrointestinal microbiota and improves symptoms in patients with chronic pouchitis S.D. McLaughlin, A. Culkin,

Bowel sonography in occlusive Crohn's disease

The role of in vitro interferonγ-release assay in differentiating intestinal tuberculosis from Crohn's disease in China Yue Li, Li-fan Zhang, Xiao-qing.

Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors Anilga Moradkhani, Linda.

Volume 65, Issue 5, Pages (May 2004)

Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.

Volume 130, Issue 6, (September 2007)

Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro Elizabeth S. Robinson, Paul Alves,

Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study D. Goletti, S. Carrara,

Sulfonamide-reactive lymphocytes detected at very low frequency in the peripheral blood of patients with drug-induced eruptions Richard S. Kalish, MD,

Volume 88, Issue 6, Pages (December 2015)

Volume 134, Issue 6, (September 2008)

Presentation transcript:

Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents Jose Domínguez, Irene Latorre Journal of Crohn's and Colitis Volume 2, Issue 3, Pages 250-254 (September 2008) DOI: 10.1016/j.crohns.2008.05.007 Copyright © 2008 European Crohn's and Colitis Organisation Terms and Conditions

Figure 1 T-SPOT.TB detects the IFN-γ produced by peripheral blood isolated mononuclear cells by means of ELISPOT method, after stimulation with ESAT-6 and CFP-10. Subjects are considered positive if there is response to one or both of the specific antigens (A). The result is considered negative when there is not response for any of the specific antigens (B). The presence of reactive antigen-specific T cells is revealed as a spot on the well. Spots can be scored manually or also with the aid of an automated ELISPOT plate reader. Test wells are scored as positive if they contain at least six spot-forming cells more than the negative control well and this number is at least twice the number of the negative control well. The result of the assay is considered indeterminate if the number of spots in the positive control is less than 20, and the response to both of the specific antigens is negative (C). Journal of Crohn's and Colitis 2008 2, 250-254DOI: (10.1016/j.crohns.2008.05.007) Copyright © 2008 European Crohn's and Colitis Organisation Terms and Conditions